Stocks Worth Watching: ONFO, TLS, ALAR, GERN

Geron, Gern, Company Profile 

Imetelstat, an investigational drug developed in-house at Geron, has the potential to advance how blood cancers are treated by altering the underlying drivers of disease. 

Nobel Prize-winning discoveries about an enzyme called telomerase and its impact on driving uncontrolled proliferation of malignant cells was our beginning. The belief in the potential of targeting and inhibiting telomerase to kill malignant cancer cells started our journey. The advancement of that idea into treatments that extend and enhance patients’ lives by altering the underlying drivers of disease is our mission.  

Our belief in this science moves us to try things others have not. Our collaborative spirit and courage allow us to see things in ways others do not. Our determination to bring patients a transformative treatment led us to forge new pathways.